Jill C. Beck, John E. Wagner, Todd E. DeFor, Claudio G

Slides:

Advertisements

Similar presentations

Galactomannan Antigen Enzyme-Linked Immunosorbent Assay for Diagnosis of Invasive Aspergillosis after Hematopoietic Stem Cell Transplantation Patrick.

Advertisements

Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen.

Promising Progression-Free Survival for Patients Low and Intermediate Grade Lymphoid Malignancies after Nonmyeloablative Umbilical Cord Blood Transplantation

Follistatin and Endoglin: Potential Biomarkers of Endothelial Damage and Non-Relapse Mortality after Myeloablative Allogeneic Hematopoietic Cell Transplantation.

Successful Remission Rates and Survival after Lymphodepleting Chemotherapy and Donor Lymphocyte Infusion for Relapsed Hematologic Malignancies Postallogeneic.

Reduced-Intensity Conditioning Followed by Related Allografts in Hematologic Malignancies: Long-Term Outcomes Most Successful in Indolent and Aggressive.

Does the Hematopoietic Cell Transplantation Specific Comorbidity Index Predict Transplant Outcomes? A Validation Study in a Large Cohort of Umbilical.

Peter Hurley, Suma Konety, Qing Cao, Daniel Weisdorf, Anne Blaes

Changing Trends of Unrelated Umbilical Cord Blood Transplantation for Hematologic Diseases in Patients Older than Fifty Years: A Eurocord-Center for International.

Survival Differences between Adolescents/Young Adults and Children with B Precursor Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplantation

Impact of Allele-Level HLA Mismatch on Outcomes in Recipients of Double Umbilical Cord Blood Transplantation Claudio G. Brunstein, Effie W. Petersdorf,

Efficacy of a Viral Load-Based, Risk-Adapted, Preemptive Treatment Strategy for Prevention of Cytomegalovirus Disease after Hematopoietic Cell Transplantation

Long-Term Results of Autologous Stem Cell Transplantation for Primary Refractory or Relapsed Hodgkin’s Lymphoma Navneet S. Majhail, Daniel J. Weisdorf,

Edward Copelan, James T. Casper, Shelly L. Carter, Jo-Anne H

Sabina Kersting, Leo F. Verdonck

Assessment of the Hematopoietic Cell Transplantation Comorbidity Index in Non- Hodgkin Lymphoma Patients Receiving Reduced-Intensity Allogeneic Hematopoietic.

David C. Yao, MD, PhD, Paolo Caimi, MD, Hillard M

Late Effects after Umbilical Cord Blood Transplantation in Very Young Children after Busulfan-Based, Myeloablative Conditioning Heather Allewelt, Jill.

Donor-to-Recipient ABO Mismatch Does Not Impact Outcomes of Allogeneic Hematopoietic Cell Transplantation Regardless of Graft Source Sharat Damodar,

Jo-Anne H. Young, Brent R. Logan, Juan Wu, John R. Wingard, Daniel J

Myeloablative, but not Reduced-Intensity, Conditioning Overcomes the Negative Effect of Flow-Cytometric Evidence of Leukemia in Acute Myeloid Leukemia

Cytomegalovirus Infection after Allogeneic Transplantation: Comparison of Cord Blood with Peripheral Blood and Marrow Graft Sources Christopher M. Walker,

Monosomal Karyotype Provides Better Prognostic Prediction after Allogeneic Stem Cell Transplantation in Patients with Acute Myelogenous Leukemia Betul.

Claudio G. Brunstein, Bruce R. Blazar, Jeffrey S

Bacteremia in Blood or Marrow Transplantation Patients: Clinical Risk Factors for Infection and Emerging Antibiotic Resistance Allison M. Bock, Qing.

Low Relapse without Excessive Transplant-Related Mortality following Myeloablative Cord Blood Transplantation for Acute Leukemia in Complete Remission:

Evaluating the Impact of Antithymocyte Globulin on Lung Function at 1 Year after Allogeneic Stem Cell Transplantation Filippo Milano, Margaret A. Au,

Higher Dose of Mycophenolate Mofetil Reduces Acute Graft-versus-Host Disease in Reduced-Intensity Conditioning Double Umbilical Cord Blood Transplantation

Claudio Brunstein, MD, PhD, Keli Hippen, Todd E

Unrelated Cord Blood Transplantation in Adult and Pediatric Acute Lymphoblastic Leukemia: Effect of Minimal Residual Disease on Relapse and Survival

The International Prognostic Index Assessed at Relapse Predicts Outcomes of Autologous Transplantation for Diffuse Large-Cell Non-Hodgkin’s Lymphoma in.

Total Marrow Lymphoid Irradiation/Fludarabine/ Melphalan Conditioning for Allogeneic Hematopoietic Cell Transplantation Lindsay G. Jensen, Tracey Stiller,

Improvement of Pulmonary Function with Imatinib Mesylate in Bronchiolitis Obliterans Following Allogeneic Hematopoietic Cell Transplantation Navneet.

A Randomized Trial of One versus Two Doses of Influenza Vaccine after Allogeneic Transplantation Nicole A. Karras, Matthew Weeres, Wendy Sessions, Xiyan.

Decreased Infections in Recipients of Unrelated Donor Hematopoietic Cell Transplantation from Donors with an Activating KIR Genotype Marcie Tomblyn,

Filippo Milano, Jason W. Chien, Ivy Riffkin, Jonathan A

Hematopoietic Cell Transplantation for Acute Leukemia and Advanced Myelodysplastic Syndrome in Fanconi Anemia Richard Mitchell, Todd Defor, John E. Wagner,

Effect of Conditioning Regimen Intensity on Acute Myeloid Leukemia Outcomes after Umbilical Cord Blood Transplantation Betul Oran, John E. Wagner, Todd.

Allogeneic Hematopoietic Stem Cell Transplantation in Adult Acute Lymphocytic Leukemia: Impact of Donor Source on Survival Priya Kumar, Todd E. Defor,

Adjusting Cyclophosphamide Dose in Obese Patients with Lymphoma Is Safe and Yields Favorable Outcomes after Autologous Hematopoietic Cell Transplantation

Favorable Overall Survival with Fully Myeloablative Allogeneic Stem Cell Transplantation for Follicular Lymphoma John Kuruvilla, Gregory Pond, Richard.

Allogeneic Hematopoietic Cell Transplantation in Children with Relapsed Acute Lymphoblastic Leukemia Isolated to the Central Nervous System Paul D. Harker-Murray,

Graft-versus-Host Disease Induced Graft-versus-Leukemia Effect: Greater Impact on Relapse and Disease-Free Survival after Reduced Intensity Conditioning

An Exploratory Analysis of Mitochondrial Haplotypes and Allogeneic Hematopoietic Cell Transplantation Outcomes Julie A. Ross, Jakub Tolar, Logan G. Spector,

Sabina Kersting, Ronald J. Hené, Hein A. Koomans, Leo F. Verdonck

Similar Invasive Fungal Infection Rates and Survival after Allogeneic Hematopoietic Cell Transplantation with Umbilical Cord Blood and Bone Marrow or.

Costs of Hematopoietic Cell Transplantation: Comparison of Umbilical Cord Blood and Matched Related Donor Transplantation and the Impact of Posttransplant.

Hematopoietic Cell Transplantation for Children with Acute Lymphoblastic Leukemia in Second Complete Remission: Similar Outcomes in Recipients of Unrelated.

Adaptive Natural Killer Cell and Killer Cell Immunoglobulin–Like Receptor–Expressing T Cell Responses are Induced by Cytomegalovirus and Are Associated.

Human Parainfluenza Virus Infection after Hematopoietic Stem Cell Transplantation: Risk Factors, Management, Mortality, and Changes over Time Celalettin.

Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data Brent R. Logan, Mei-Jie Zhang,

Pauline Damien, David S. Allan

Galactomannan Antigen Enzyme-Linked Immunosorbent Assay for Diagnosis of Invasive Aspergillosis after Hematopoietic Stem Cell Transplantation Patrick.

Protective Effect of Cytomegalovirus Reactivation on Relapse after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients Is.

Chronic Graft-Versus-Host Disease (cGVHD) following Unrelated Donor Hematopoietic Stem Cell Transplantation (HSCT): Higher Response Rate In Recipients.

Richard Mitchell, John E. Wagner, Claudio Brunstein, Qing Cao, David H

Double Umbilical Cord Blood Transplantation after Novel Myeloablative Conditioning Using a Regimen of Fludarabine, Busulfan, and Total Lymphoid Irradiation

Richard Mitchell, John E. Wagner, Claudio G

Reduced-Intensity Allogeneic Transplant in Patients Older Than 55 Years: Unrelated Umbilical Cord Blood Is Safe and Effective for Patients without a Matched.

Umbilical Cord Blood Transplantation Outcomes in Acute Myelogenous Leukemia/Myelodysplastic Syndrome Patients Aged ≥70 Years Karamjeet S. Sandhu, Claudio.

Blood and Marrow Transplant Handbook

Comparable Outcomes after HLA-Matched Sibling and Alternative Donor Hematopoietic Cell Transplantation for Children with Fanconi Anemia and Severe Aplastic.

Extramedullary Relapse of Acute Myelogenous Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: Better Prognosis Than Systemic Relapse

Mammen Chandy Biology of Blood and Marrow Transplantation

Classification of HLA-Matching for Retrospective Analysis of Unrelated Donor Transplantation: Revised Definitions to Predict Survival Daniel Weisdorf,

Matching at Human Leukocyte Antigen-C Improved the Outcomes after Double Umbilical Cord Blood Transplantation for Recipients of Two to Four of Six Human.

In Memoriam: E. Donnall Thomas

Promising Progression Free and Overall Survival Using a Novel (CY/FLU/TBI) Reduced-Intensity Conditioning (RIC) Regimen for Allogeneic Sibling Stem Cell.

Claudio G. Brunstein, David H. McKenna, Todd E

Sirolimus and Mycophenolate Mofetil as Calcineurin Inhibitor–Free Graft-versus-Host Disease Prophylaxis for Reduced-Intensity Conditioning Umbilical Cord.

Presentation transcript:

Impact of Cytomegalovirus (CMV) Reactivation after Umbilical Cord Blood Transplantation Jill C. Beck, John E. Wagner, Todd E. DeFor, Claudio G. Brunstein, Mark R. Schleiss, Jo-Anne Young, Daniel H. Weisdorf, Sarah Cooley, Jeffrey S. Miller, Michael R. Verneris Biology of Blood and Marrow Transplantation Volume 16, Issue 2, Pages 215-222 (February 2010) DOI: 10.1016/j.bbmt.2009.09.019 Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 Cumulative incidence of CMV reactivation by conditioning regimen. There is no significant difference between the myeloablative and nonmyeloablative conditioning. Biology of Blood and Marrow Transplantation 2010 16, 215-222DOI: (10.1016/j.bbmt.2009.09.019) Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 Cumulative incidence of CMV reactivation by GVHD prophylaxis regimen. There is no significant difference between the ATG containing regimen (CsA/methylprednisone/ATG) and the non-ATG containing regimen (CsA/MMF). Biology of Blood and Marrow Transplantation 2010 16, 215-222DOI: (10.1016/j.bbmt.2009.09.019) Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions